New York, New York--(Newsfile Corp. - August 31, 2020) - NanoViricides, Inc. (AMEX: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has been the focus of recent coverage on leading financial news website and publisher, Small Caps Daily. NanoViricides' progress on developing a therapy to combat COVID-19 and also addressing the existing, global concern of how to get kids back to their classrooms, were two of the major topics covered in the Small Caps Daily article. Globally, nearly 850,000 lives have already been lost due to COVID-19, so it is very promising that NanoViricides' drug candidates showed strong effectiveness in the animal model as compared to remdesivir and have also outperformed favipiravir in its cell culture studies. NanoViricides has successfully carried out a safety and tolerability study on rats and the excellent results have now cleared the way for NanoViricides for moving forward to human clinical trials.
Key Takeaways from the SmallCapsDaily article featuring NanoViricides:
NanoViricides is launching a novel drug as opposed to most other drug candidates in the market by other large pharma companies such as favipiravir and remdesivir which are essentially repurposed drugs.
Data indicates that more than 2,000 students, teachers and staff members across five states have been quarantined after at least 230 positive coronavirus cases were reported where schools attempted to restart and there has been a 90% increase in the number of COVID-19 cases among children in the U.S. over the past month.
Research implies that NanoViricides' drug candidates which could identify and fight off the alternative coronavirus infection similar to common cold attacking the same cellular receptors, also has the ability to attack and fight the COVID-19.
For more insight into NanoViricides, Inc., and to continue reading the Small Caps Daily featured article, please click here: https://smallcapsdaily.com/nanoviricides-working-to-get-kids-back-to-school-safely/.
About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is in the process of completing an IND application to the US FDA for this drug candidate. The Company cannot project an exact date for filing an IND because of its dependence on a number of external collaborators and consultants, and the effects of recent COVID-19 restrictions.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus and Ebola/Marburg viruses. The Company has executed a Memorandum of Understanding with TheraCour that provides a limited license for research and development for drugs against human coronaviruses. The Company intends to obtain a full license and has begun the process for the same. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. CMC refers to "Chemistry, Manufacture, and Controls".
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/62860